🎁 Black Friday: up to 50% off of annual plans
Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.1636
-0.0230 (-12.33%)
At close: Nov 20, 2026, 4:00 PM EST
0.1666
+0.0030 (1.83%)
After-hours: Nov 20, 2026, 7:46 PM EST

Vistagen Therapeutics Stock Forecast

VTGN's stock price has decreased by -96.36% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 3 analysts with 12-month price forecasts for Vistagen Therapeutics stock have an average target of $1.00, which predicts a 511.25% increase from the current stock price of 0.16.

Price Target: $1.00 (+511.25%)
Analyst Consensus: Hold

Price Target

Chart
TargetLowAverageMedianHigh
Price$1.00$1.00$1.00$1.00
Change+511.25%+511.25%+511.25%+511.25%
* Price targets were last updated on Dec 17, 2025.

Analyst Ratings

The average analyst rating for Vistagen Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Chart
RatingApr '26May '26Jun '26Aug '26Sep '26Nov '26
Strong Buy000000
Buy000000
Hold554443
Sell000000
Strong Sell000000
Total554443

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
William Blair
William Blair
Hold
Maintains
n/a
HoldMaintainsn/an/aSep 23, 2026
Jefferies
Jefferies
Hold
Downgrades
$15 → $0.9
HoldDowngrades$15 → $0.9+450.12%Dec 17, 2025
Maxim Group
Maxim Group
Hold
Downgrades
n/a
HoldDowngradesn/an/aDec 17, 2025
Lucid Capital
Lucid Capital
Hold
Downgrades
$19 → $1
HoldDowngrades$19 → $1+511.25%Dec 17, 2025

Financial Forecast

Revenue This Year
1.70M
from 1.27M
Increased by 33.96%
Revenue Next Year
n/a
from 1.70M
Decreased by -100.00%
EPS This Year
-1.48
from -1.83
EPS Next Year
-1.54
from -1.48
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026FY 2027E
Period EndingMar 31, 2022Mar 31, 2023Mar 31, 2024Mar 31, 2025Mar 31, 2026Mar 31, 2027
Revenue
1.11M-227.00K1.06M486.00K1.27M1.70M
Revenue Growth
1.78%---54.32%161.11%33.96%
Gross Profit
1.11M-227.00K1.06M486.00K1.27M1.55M
Gross Margin
100.00%100.00%100.00%100.00%100.00%91.00%
Operating Income
-47.78M-59.27M-33.02M-55.97M-72.13M-62.96M
Net Income
-47.76M-59.25M-29.36M-51.42M-69.69M-47.00M
EPS
-----1.83-1.48
Free Cash Flow
-----66.59M-99.00M
No. Analysts
-----2
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202720282029
High1.9M
Avg1.7M
Low1.5M

Revenue Growth

Revenue Growth202720282029
High
49.7%
Avg
34.0%
Low
18.2%

EPS Forecast

EPS202720282029
High-1.45
Avg-1.48
Low-1.50

EPS Growth

EPS Growth202720282029
High-
Avg-
Low-